Jump to main content
Topic: Market Analysis
-
Xeljanz, the FDA, and nine years of patient harm
Read More
-
Atypical antipsychotics: Decades of use, unfathomable harms
Read More
-
The Drugs at the Heart of Our Pricing Crisis
Read More
-
Biosimilars: Market Changes do not equal policy success
Read More
-
Modeling P-quad
Read More
-
Time to Throw in the Towel on Biosimilars
Read More
-
Understanding the Rewards of Successful Drug Development: Thinking Inside the Box
Read More
-
Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries
Read More
-
Abandon Biosimilars as Biologics are Natural Monopolies
Read More
-
DPL responds to HHS Blueprint (May 16, 2018)
Read More